Development of recombinant lactococcus lactis displaying albumin-binding domain variants against Shiga toxin 1 b subunit

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Zadravec, Petra ^a,b   Mareèková, Lucie ^c   Petroková, Hana ^c   Hodnik, Vesna ^b,d   Nanut, Milica Periší ^a   Anderluh, Gregor ^b,d   Štrukelj, Borut ^a,b   Malý, Petr ^c   Berlec, Aleš ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c Institute of Biotechnology CAS   (Czech Republic)

^d NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN BINDING DOMAIN FUSION PROTEIN; HYBRID PROTEIN; SHIGA TOXIN 1 B SUBUNIT; UNCLASSIFIED DRUG; VEROTOXIN 1; ALBUMINOID; IMMOBILIZED PROTEIN; PROTEIN BINDING; PROTEIN SUBUNIT; RECOMBINANT PROTEIN;

ABDWT GENE; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; CARBOXY TERMINAL SEQUENCE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENETIC VARIATION; GOLGI COMPLEX; H6 ABDWT GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; LACTOCOCCUS LACTIS; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; RIBOSOME; S1B22 GENE; S1B26 GENE; SIGNAL TRANSDUCTION; STX1B GENE; SURFACE PLASMON RESONANCE; CELL SURFACE DISPLAY; CHEMISTRY; FLOW CYTOMETRY; GENETIC RECOMBINATION; GENETICS; HELA CELL LINE; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN SUBUNIT; PROTEIN TRANSPORT; SEQUENCE HOMOLOGY;

ALBUMINS; CELL SURFACE DISPLAY TECHNIQUES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELA CELLS; HUMANS; IMMOBILIZED PROTEINS; LACTOCOCCUS LACTIS; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN SUBUNITS; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; RIBOSOMES; SEQUENCE HOMOLOGY, AMINO ACID; SHIGA TOXIN 1; SURFACE PLASMON RESONANCE;

EID: 84991229752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162625     Document Type: Article

References (41)

1. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev. 1998; 11(3):450-79. PMID: 9665978,
2. ÒBrien AD, Holmes RK. Shiga and Shiga-Like Toxins. Microbiol Rev. 1987; 51(2):206-20. PMID: 3299029
3. Johannes L, Römer W. Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol. 2010. doi: 10.1038/nrmicro2279
4. Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther. 2012; 6:195-208. PMID: 22888220.
5. Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996; 76(4):949-66. PMID: 8874490.
6. Sandvig K. Shiga toxins. Toxicon. 2001; 39(11):1629-35. doi: 10.1016/S0041-0101(01)00150-7 PMID: 11595626.
7. Melton-Celsa AR, O'Brien AD. New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli. Microbiol Spectr. 2014; 2(5). doi: 10.1128/microbiolspec.EHEC-0013-2013 PMID: 26104346.
8. Rahal EA, Fadlallah SM, Nassar FJ, Kazzi N, Matar GM. Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype. Front Cell Infect Microbiol. 2015; 5:24. doi: 10.3389/fcimb.2015.00024 PMID: 25853096.
9. Skrlec K, Strukelj B, Berlec A. Non-immunoglobulin scaffolds: a focus on their targets. Trends Biotechnol. 2015; 33(7):408-18. doi: 10.1016/j.tibtech.2015.03.012 PMID: 25931178.
10. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. 2009; 13(3):245-55. doi: 10.1016/j.cbpa.2009.04.627 PMID: 19501012.
11. Ahmad JN, Li J, Biedermannova L, Kuchar M, Sipova H, Semeradtova A, et al. Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins. 2012; 80 (3):774-89. doi: 10.1002/prot.23234 PMID: 22113774.
12. Kuchar M, Vankova L, Petrokova H, Cerny J, Osicka R, Pelak O, et al. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins. 2014; 82(6):975-89. doi: 10.1002/prot.24472 PMID: 24549990.
13. Mareckova L, Petrokova H, Osicka R, Kuchar M, Maly P. Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94). Protein Cell. 2015. doi: 10. 1007/s13238-015-0194-9 PMID: 26264490.
14. Mohsin M, Guenther S, Schierack P, Tedin K, Wieler LH. Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli. Int J Med Microbiol. 2015; 305(1):20-6. doi: 10.1016/j.ijmm.2014.10.003 PMID: 25465158.
15. Reissbrodt R, Hammes WP, dal Bello F, Prager R, Fruth A, Hantke K, et al. Inhibition of growth of Shiga toxin-producing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett. 2009; 290 (1):62-9. doi: 10.1111/j.1574-6968.2008.01405.x PMID: 19016876.
16. Ogawa M, Shimizu K, Nomoto K, Tanaka R, Hamabata T, Yamasaki S, et al. Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157:H7 by probiotic Lactobacillus strains due to production of lactic acid. Int J Food Microbiol. 2001; 68(1-2):135-40. PMID: 11545213.
17. Ravnikar M, Strukelj B, Obermajer N, Lunder M, Berlec A. Engineered Lactic Acid Bacterium Lactococcus lactis Capable of Binding Antibodies and Tumor Necrosis Factor Alpha. Appl Environ Microbiol. 2010; 76(20):6928-32. doi: 10.1128/aem.00190-10 PMID: 20802083
18. Zadravec P, Strukelj B, Berlec A. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl Environ Microbiol. 2015; 81(6):2098-106. doi: 10.1128/AEM.03694-14 PMID: 25576617.
19. Zadravec P, Strukelj B, Berlec A. Heterologous surface display on lactic acid bacteria: non-GMO alternative? Bioengineered. 2015; 6(3):179-83. doi: 10.1080/21655979.2015.1040956 PMID: 25880164.
20. Steen A. Cell Wall Attachment of a Widely Distributed Peptidoglycan Binding Domain Is Hindered by Cell Wall Constituents. J Biol Chem. 2003; 278(26):23874-81. doi: 10.1074/jbc.M211055200 PMID: 12684515
21. Buist G, Kok J, Leenhouts KJ, Dabrowska M, Venema G, Haandrikman AJ. Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of Lactococcus lactis,a muramidase needed for cell separation. J Bacteriol. 1995; 177(6):1554-63. PMID: 7883712.
22. Steen A, Buist G, Horsburgh GJ, Venema G, Kuipers OP, Foster SJ, et al. AcmA of Lactococcus lactis is an N-acetylglucosaminidase with an optimal number of LysM domains for proper functioning. FEBS J. 2005; 272(11):2854-68. doi: 10.1111/j.1742-4658.2005.04706.x PMID: 15943817.
23. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med. 2000; 6(3):265-70. PMID: 10700227
24. Pinyon RA, Paton JC, Paton AW, Botten JA, Morona R. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis. 2004; 189(9):1547-55. doi: 10.1086/383417 PMID: 15116289.
25. Bondos SE, Bicknell A. Detection and prevention of protein aggregation before, during, and after purification. Anal Biochem. 2003; 316(2):223-31. doi: 10.1016/S0003-2697(03)00059-9 PMID: 12711344.
26. Tsumoto K, Ejima D, Kumagai I, Arakawa T. Practical considerations in refolding proteins from inclusion bodies. Protein Expr Purif. 2003; 28(1):1-8. doi: 10.1016/S1046-5928(02)00641-1 PMID: 12651100.
27. Oneda H, Inouye K. Refolding and recovery of recombinant human matrix metalloproteinase 7 (matrilysin) from inclusion bodies expressed by Escherichia coli. J Biochem. 1999; 126(5):905-11. PMID: 10544284.
28. de Ruyter PG, Kuipers OP, de Vos WM. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol. 1996; 62(10):3662-7. PMID: 8837421.
29. Kuipers OP, Beerthuyzen MM, Siezen RJ, De Vos WM. Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem. 1993; 216(1):281-91. PMID: 7689965.
30. Kuipers OP, de Ruyter PGGA, Kleerebezem M, de Vos WM. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol. 1998; 64(1):15-21. doi: 10.1016/S0168-1656(98)00100-X
31. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol. 2005; 68(6):705-17. doi: 10.1007/s00253-005-0107-6 PMID: 16088349
32. Ashkenazi S, Cleary TG. Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor. J Clin Microbiol. 1989; 27(6):1145-50. PMID: 2666433.
33. Berlec A, Malovrh T, Zadravec P, Steyer A, Ravnikar M, Sabotic J, et al. Expression of a hepatitis A virus antigen in Lactococcus lactis and Escherichia coli and evaluation of its immunogenicity. Appl Microbiol Biotechnol. 2013; 97(10):4333-42. doi: 10.1007/s00253-013-4722-3 PMID: 23371298.
34. Berlec A, Zadravec P, Jevnikar Z, Strukelj B. Identification of candidate carrier proteins for surface display on Lactococcus lactis by theoretical and experimental analyses of the surface proteome. Appl Environ Microbiol. 2011; 77(4):1292-300. doi: 10.1128/AEM.02102-10 PMID: 21183632.
35. Zadravec P, Mavric A, Bogovic Matijasic B, Strukelj B, Berlec A. Engineering BmpA as a carrier for surface display of IgG-binding domain on Lactococcus lactis. Protein Eng Des Sel. 2014; 27(1):21-7. doi: 10.1093/protein/gzt059 PMID: 24336343.
36. Lindholm A, Smeds A, Palva A. Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis. Appl Environ Microbiol. 2004; 70(4):2061-71. PMID: 15066797.
37. Kim JH, Lingwood CA, Williams DB, Furuya W, Manolson MF, Grinstein S. Dynamic measurement of the pH of the Golgi complex in living cells using retrograde transport of the verotoxin receptor. J Cell Biol. 1996; 134(6):1387-99. PMID: 8830769.
38. Neri P, Shigemori N, Hamada-Tsutsumi S, Tsukamoto K, Arimitsu H, Shimizu T, et al. Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library. Vaccine. 2011; 29(33):5340-6. doi: 10.1016/j.vaccine.2011.05.093 PMID: 21664401.
39. Lipovsek D, Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods. 2004; 290(1-2):51-67. doi: 10.1016/j.jim.2004.04.008 PMID: 15261571.
40. Richter A, Eggenstein E, Skerra A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014; 588(2):213-8. doi: 10.1016/j.febslet.2013.11.006 PMID: 24239535.
41. Dieye Y, Usai S, Clier F, Gruss A, Piard JC. Design of a protein-targeting system for lactic acid bacteria. J Bacteriol. 2001; 183(14):4157-66. doi: 10.1128/JB.183.14.4157-4166.2001 PMID: 11418555.